Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition (Q24801995)

6 July 2017

1 reference

23 December 2020

Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition (English)

1 reference

Erb-b2 receptor tyrosine kinase 2

6 July 2017

1 reference

23 December 2020

1 reference

18 October 2019

1 reference

18 December 2019

1 reference

23 December 2020

I Correa

1

1 reference

6 July 2017

T Plunkett

series ordinal

2

1 reference

6 July 2017

language of work or name

English

0 references

publication date

20 September 2001

15 references

6 July 2017

13 March 2019

3 April 2019

20 June 2019

19 June 2019

17 June 2019

31 July 2019

2 August 2019

7 August 2019

28 September 2019

12 October 2019

18 October 2019

15 December 2019

18 December 2019

23 December 2020

Breast Cancer Research

15 references

6 July 2017

13 March 2019

3 April 2019

20 June 2019

19 June 2019

17 June 2019

31 July 2019

2 August 2019

7 August 2019

28 September 2019

12 October 2019

18 October 2019

15 December 2019

18 December 2019

23 December 2020

3

1 reference

6 July 2017

issue

6

1 reference

6 July 2017

page(s)

399-403

1 reference

Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting

6 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Challenges to the development of antigen-specific breast cancer vaccines

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Progress in human tumour immunology and immunotherapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Clinical trials of HER-2/neu-specific vaccines.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

The makings of a tumor rejection antigen

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.

30 May 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR330

Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR330

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=138708

HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer

28 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/11737893

12 December 2020

Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing

1 reference

https://pubmed.ncbi.nlm.nih.gov/11737893

12 December 2020

Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/11737893

12 December 2020

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://pubmed.ncbi.nlm.nih.gov/11737893

12 December 2020

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11737893

12 December 2020

Identifiers

DOI

10.1186/BCR330

1 reference

Dimensions Publication ID

6 July 2017

0 references

1 reference

6 July 2017

1 reference